NYSE Arca · AZTR
Azitra Inc
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AZTR: Nov 11, 2026
Azitra Inc Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.2. The reported EPS for the same quarter last year was $-6.7.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Dec 2026 | $-0.20 | $-0.20 | $-0.20 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews- Fintel · Oct 29, 6:02 PM EDTAzitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical TrialAzitra, Inc. has announced amendments to its ongoing Phase 1/2 clinical trial of ATR04-484 that expand patient eligibility to include individuals with rash associated with KRAS and MEK inhibitors. The expanded eligibility also includes patients with neurofibromatosis type 1 (NF1)
- Fintel · Oct 26, 11:28 AM EDTAzitra, Inc. Pauses ATM Program and Announces Ex Vivo Results for ATR-COSFAzitra, Inc. announced that, effective October 26, 2026, it has decided not to utilize its at-the-market offering program under the sales agreement dated September 28, 2026, with A.G.P./Alliance Global Partners for the foreseeable future. From September 28, 2026 through October 2
- Fintel · Oct 22, 7:14 PM EDTAzitra, Inc. Announces 1-for-10 Reverse Stock SplitAzitra, Inc. filed a certificate of amendment to its Second Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on October 22, 2026, to effectuate a 1-for-10 reverse stock split of its outstanding common stock. The reverse stock
- RTTNews · Oct 16, 9:19 AM EDTAzitra To Implement 1-for-10 Reverse Stock Split(RTTNews) – Friday, Azitra, Inc. (AZTR) announced plans to implement a 1-for-10 reverse stock split, effective October 26, 2026. The company's shares will continue trading under the AZTR ticker on a split-adjusted basis.
- Fintel · Oct 2, 9:34 AM EDTAzitra Consensus Price Target Decreased by 13.55% to $0.68The average one-year price target for Azitra (NYSEAM:AZTR) has been revised to $0.68 / share on October 2, 2026, a decrease of 13.55% from the prior estimate of $0.79 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constit
- RTTNews · Jun 22, 11:10 PM EDTTop Biotech Gainers: TNON Files S-1, NVCT Inks License Deal, FTH On Watch, RGNX To Resubmit BLA(RTTNews) – Monday's top gainers include Tenon, following a Form S-1 filing; Azitra, which recently outlined its strategic reorientation and 2026 outlook; Nuvectis, after announcing a licensing deal with Haisco; and REGENXBIO, which is gearing up to resubmit its BLA for its Hunte
- Fintel · Mar 27, 5:34 AM EDTAzitra (AZTR) Price Target Decreased by 50.00% to 1.38The average one-year price target for Azitra (NYSEAM:AZTR) has been revised to $1.38 / share. This is a decrease of 50.00% from the prior estimate of $2.75 dated February 21, 2026. The price target is an average of many targets provided by analysts. The latest
- RTTNews · Mar 19, 8:34 PM EDTAzitra Prices Private Placement To Advance New Cosmetic Protein & Peptide Programs; Stock Up(RTTNews) – Shares of Azitra, Inc. (AZTR) were up in overnight trading, rising sharply after the company announced the price of a private placement financing of up to approximately $31.4 million.
- RTTNews · Mar 16, 4:01 AM EDTAzitra Gets NYSE American Listing Compliance Notice(RTTNews) – Azitra, Inc. (AZTR), a clinical-stage biopharmaceutical company, announced that it has received a notice from NYSE American LLC stating that it is not in compliance with the continued listing standards of the NYSE American Company Guide. As per the notice, Azitra has
- Fintel · Dec 6, 5:55 AM ESTAzitra (AZTR) Price Target Decreased by 77.48% to 2.75The average one-year price target for Azitra (NYSEAM:AZTR) has been revised to $2.75 / share. This is a decrease of 77.48% from the prior estimate of $12.23 dated November 14, 2025. The price target is an average of many targets provided by analysts. The lates
- Fintel · Sep 30, 6:19 PM EDTAzitra (AZTR) Price Target Decreased by 27.99% to 12.23The average one-year price target for Azitra (NYSEAM:AZTR) has been revised to $12.23 / share. This is a decrease of 27.99% from the prior estimate of $16.98 dated September 10, 2025. The price target is an average of many targets provided by analysts. The lat
- RTTNews · Sep 18, 10:32 AM EDTAzitra's ATR-04 Gets FDA Fast Track Designation For Skin Rash Linked To EGFR Inhibitors(RTTNews) – Azitra, Inc. (AZTR) Wednesday announced the receipt of Fast Track Designation from the FDA for ATR-04, a topical treatment targeting moderate to severe skin rash linked to Epidermal Growth Factor Receptor inhibitors or EGFRi, and their associated dermal toxicity.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Azitra Inc from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.